XOFIGO® (radium-223 dichloride) in combination with enzalutamide significantly increased radiological progression-free survival (rPFS) for patients with metastatic castration-resistant prostate cancer ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from ...
Algeta said today it received a “preliminary acquisition proposal” from Bayer worth NOK 14.8 billion ($2.42 billion), as the German pharma and chemical conglomerate seeks to acquire its partner in ...
WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer’s oncology and women’s health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results